Tregalizumab

From WikiProjectMed
Jump to navigation Jump to search
Tregalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetCD4
Clinical data
Other namesBT-061
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Tregalizumab is an immunomodulator.[1] It is also known as BT-061. Tregalizumab binds to domain 2 of CD4,[2] and activates Regulatory T cells (Tregs).[3]

References

  1. ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
  2. ^ Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, et al. (April 2015). "A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway". Immunology and Cell Biology. 93 (4): 396–405. doi:10.1038/icb.2014.102. PMC 4407014. PMID 25512343.
  3. ^ König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J (Jan 2016). "Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells". Frontiers in Immunology. 7: 11. doi:10.3389/fimmu.2016.00011. PMC 4724712. PMID 26834751.